Satraplatin

Summary

Satraplatin (CHEMBL3833367) is a phase-3 clinical-stage small molecule (ATC L01XA04); indicated across 6 conditions including neoplasm and breast neoplasm.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• ATC class: L01XA04
• Indications: 6 conditions
• Clinical trials: 13

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL3833367
Name	Satraplatin
Type	Small molecule
Max phase	3
ATC	L01XA04

Also known as: BMS-182751, BMY-45594, JM-216, NSC-744226, Satraplatin, Satraplatine, Satraplatino, SATRAPLATIN

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

6 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
neoplasm	3	MONDO:0005070	EFO:0000616
breast neoplasm	2	MONDO:0021100	MONDO:0007254
lung neoplasm	2	MONDO:0021117	MONDO:0008903
non-small cell lung carcinoma	1	MONDO:0005233	EFO:0003060

2 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 13.

Phase distribution

Phase	Trials
PHASE1	5
PHASE2	4
PHASE3	2
PHASE1/PHASE2	1
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00069745	PHASE3	COMPLETED	Satraplatin in Hormone Refractory Prostate Cancer Patients Previously Treated With One Cytotoxic Chemotherapy Regimen
NCT00450970	PHASE3	TERMINATED	Expanded Access Study of Satraplatin Plus Prednisone in Patients With Hormone Refractory Prostate Cancer (HRPC)
NCT00093132	PHASE1/PHASE2	TERMINATED	Satraplatin for Locally Advanced Non-Small Cell Lung Cancer With Simultaneous Radiotherapy
NCT00265655	PHASE2	COMPLETED	Satraplatin for Patients With Metastatic Breast Cancer (MBC)
NCT00370383	PHASE2	COMPLETED	A Study Comparing Sequential Satraplatin & Erlotinib to Erlotinib in Unresectable Stage 3/4 Non-small-cell Lung Cancer (NSCLC)
NCT00634647	PHASE2	COMPLETED	Satraplatin and Prednisone to Treat Prostate Cancer
NCT01289067	PHASE2	COMPLETED	Utilizing A Genomic Sig for BRCAness to Eval the Efficacy of Satraplatin in Men With Met. Castration Resistant Prostate Ca
NCT00125411	PHASE1	TERMINATED	Study of Satraplatin (JM-216) in Combination With Docetaxel
NCT00313456	PHASE1	TERMINATED	A Phase I Study of the Oral Platinum Agent Satraplatin in Combination With Weekly Docetaxel
NCT00329329	PHASE1	TERMINATED	Study of Satraplatin With Capecitabine to Treat Advanced Solid Malignancies
NCT00473720	PHASE1	COMPLETED	Phase I Study of the Combination of Satraplatin and Abraxane in Advanced Cancers
NCT01259479	PHASE1	COMPLETED	Satraplatin in Children and Young Adults With Refractory Solid Tumors Including Brain Tumors
NCT00499694	Not specified	COMPLETED	Satraplatin and Bevacizumab in Treating Patients With Metastatic Prostate Cancer Previously Treated With Docetaxel

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).